Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Patent metadata

Field	Value
Publication number	US-9872850-B2
Application number	US-201113336841-A
Country	US
Kind code	B2
Filing date	Dec 23, 2011
Priority date	Dec 23, 2010
Publication date	Jan 23, 2018
Grant date	Jan 23, 2018

Abstract

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

First claim

We claim:

1. A method of enhancing muscle performance, comprising:
administering to a mammal in need thereof an effective amount of a urolithin, to increase muscle performance.

2. The method of claim 1 , wherein the muscle performance is selected from the group consisting of strength, speed, and endurance.

3. The method of claim 1 , wherein the urolithin is selected from the group consisting of urolithin A, urolithin B, and a combination of urolithin A and urolithin B.

4. The method of claim 1 , wherein the urolithin is administered orally.

5. The method of claim 1 , wherein the urolithin is administered parenterally.

6. The method of claim 1 , wherein the urolithin is administered at least weekly.

7. The method of claim 1 , wherein the urolithin is administered at least daily.

8. The method of claim 1 , wherein the urolithin is urolithin A.

9. The method of claim 1 , wherein the urolithin is urolithin B.

10. The method of claim 1 , wherein the urolithin is urolithin C.

11. The method of claim 1 , wherein the urolithin is urolithin D.

12. The method of claim 1 , wherein said enhancement is improved muscle function.

13. The method of claim 1 , wherein said enhancement is increased muscle mass.

14. The method of claim 1 , wherein the mammal has cachexia.

15. The method of claim 1 , wherein the mammal has muscle atrophy.

16. The method of claim 1 , wherein the mammal does not have a viral infection.

17. The method of claim 1 , wherein the mammal is a human.

18. The method of claim 17 , wherein the urolithin is administered orally.

19. The method of claim 18 , wherein the urolithin is urolithin A.

20. A method of maintaining muscle performance, comprising:
administering to a mammal in need thereof an effective amount of a urolithin, to maintain muscle performance.

21. The method of claim 20 , wherein the muscle performance is selected from the group consisting of strength, speed, and endurance.

22. The method of claim 20 , wherein the urolithin is urolithin A.

23. The method of claim 20 , wherein the urolithin is administered orally.

24. The method of claim 20 , wherein the urolithin is administered parenterally.

25. The method of claim 20 , wherein the urolithin is administered at least weekly.

26. The method of claim 20 , wherein the urolithin is administered at least daily.

27. The method of claim 20 , wherein said method maintains muscle function.

28. The method of claim 20 , wherein said method maintains muscle mass.

29. The method of claim 20 , wherein the mammal has cachexia.

30. The method of claim 20 , wherein the mammal has muscle atrophy.

31. The method of claim 20 , wherein the mammal is a human.

32. The method of claim 31 , wherein the urolithin is administered orally.

33. The method of claim 31 , wherein the urolithin is urolithin A.

34. The method of claim 20 , wherein the mammal is a human; the urolithin is administered orally; and the urolithin is urolithin A.

35. The method of claim 1 , wherein the urolithin is administered in the form of a pharmaceutical.

36. The method of claim 1 , where the urolithin is administered in the form of a medical food.

37. The method of claim 1 , wherein the urolithin is administered in the form of a functional food.

38. The method of claim 1 , wherein the urolithin is administered in the form of a food additive.

39. The method of claim 1 , wherein the urolithin is administered in the form of a dietary supplement.

40. The method of claim 1 , wherein the urolithin is administered in the form of a food product.

41. The method of claim 20 , wherein the urolithin is administered in the form of a pharmaceutical.

42. The method of claim 20 , where the urolithin is administered in the form of a medical food.

43. The method of claim 20 , wherein the urolithin is administered in the form of a functional food.

44. The method of claim 20 , wherein the urolithin is administered in the form of a food additive.

45. The method of claim 20 , wherein the urolithin is administered in the form of a dietary supplement.

46. The method of claim 20 , wherein the urolithin is administered in the form of a food product.

Assignees

• Rinsch Christopher Lawrence
• Blanco-Bose William
• Schneider Bernard
• Thomas Charles
• Sandi Carmen
• Auwerx Johan
• Andreux Penelope
• Houtkooper Richardus
• Pirinen Eija
• Mouchiroud Laurent
• Genoux David
• Amazentis Sa

Inventors

• Rinsch Christopher Lawrence
• Blanco-Bose William
• Schneider Bernard
• Thomas Charles
• Sandi Carmen
• Auwerx Johan
• Andreux Penelope
• Houtkooper Richardus
• Pirinen Eija
• Mouchiroud Laurent
• Genoux David

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title